Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-NG-methylarginine hydrochloride 546C88
- 1 May 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (5) , 1263-1268
- https://doi.org/10.1097/00003246-200005000-00001
Abstract
Objective: The nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride (L-NMMA HC1 546C88) causes reductions in cardiac output (CO), a potential limitation to clinical application. This drop in CO exceeds that from phenylephrine at matched systemic arterial pressure. We tested the hypothesis that the greater fall in CO attributable to L-NMMA primarily reflects a difference in venoconstriction between agents, such that phenylephrine produces larger increases in preload (an independent determinant of CO). Design: Random infusion of phenylephrine or L-NMMA. Setting: An animal research laboratory. Subjects: Eight healthy, conscious, male dogs. Interventions: L-NG-methylarginine hydrochloride (20 mg/kg for 1 hr) and phenylephrine (0.5 to 3 μg/kg/min) were administered into eight dogs chronically instrumented to measure left ventricular pressure and dimension. Data were measured at a constant heart rate (140 beats/min) to render CO proportional to stroke dimension. Measurements and Main Results: At a matched increase in afterload (effective arterial elastance), L-NMMA increased preload (end-diastolic dimension) to a lesser degree (3.8% ± 1.5%, p < .05) than phenylephrine (9.6% ± 1.6%, p < .05 vs. L-NMMA). Neither L-NMMA nor phenylephrine affected the slope of the end-systolic pressure dimension relationship, although L-NMMA shifted the relationship rightward (1.7 ± 0.7 mm, p < .05), consistent with a mild negative inotropic effect. L-NMMA decreased the stroke dimension to a greater extent than phenylephrine (−24.1% ± 6.8% and −10.6% ± 3.4%, respectively, p < .05). Conclusions: Differential CO responses to phenylephrine and L-NMMA were primarily attributable to changes in preload. Variable venular vs. arteriolar constrictor effects must be considered when evaluating the integrated cardiovascular response to a vasoactive agent.Keywords
This publication has 22 references indexed in Scilit:
- An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shockCritical Care Medicine, 1999
- The role of nitric oxide in cardiac depression induced by interleukin‐1β and tumour necrosis factor‐αBritish Journal of Pharmacology, 1995
- Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans.Circulation, 1994
- Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogsEuropean Journal of Pharmacology, 1991
- Regional and cardiac haemodynamic effects of NG‐nitro‐l‐arginine methyl ester in conscious, Long Evans ratsBritish Journal of Pharmacology, 1990
- NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein.Proceedings of the National Academy of Sciences, 1990
- Control of regional blood flow by endothelium-derived nitric oxide.Hypertension, 1990
- Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness.Proceedings of the National Academy of Sciences, 1989
- Role of endothelium-derived nitric oxide in the regulation of blood pressure.Proceedings of the National Academy of Sciences, 1989
- Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships.Circulation, 1987